본문 바로가기
KERD
논문KCI 등재

우울증과 유전자-환경 상호작용

Depression and Gene-Environment Interaction

김용구
대한신경정신의학회 (Korean Neuropsychiatric Association)|2010.11|신경정신의학 (JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION)|제49권 제6호|pp. 538-545

2

조회

0

다운로드

1

인용

0

참고문헌

주제분류정신과학

초록

Major depressive disorder (MDD) is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment. MDD is also a complex and heterogeneous disorder, at etiological, phenotypical, and biological levels. The gene or series of genes, which cause MDD, have so far not been identified. However, certain genetic variations, called polymorphisms, may increase the risk of MDD in a susceptible person. In addition, environmental stress also is a common precipitating factor of MDD. Various stressful life-experiences-prenatal stress, aversive early life experiences, ongoing or recent psychosocial stress-are important en-vironmental factors contributing to the development of MDD. Nevertheless, not all persons ex-posed to these stresses become depressed. Environmental stress interacts with a person’s ge-netic makeup to influence his or her risk for developing MDD. It is the combination of genes, early life stress, and ongoing stress, which may ultimately determine an individual’s responsiveness to stress and vulnerability to MDD. Consequently, the gene and environment interactions may impact multiple neurobiological systems implicated in MDD. The gene-environment interaction in the pa-thophysiology of MDD leads to advances in personalized medicine by means of genotyping for inter-individual variability in drug action and metabolism. Such concept may explain why some subjects become depressed while others remain unaffected.

Abstract

Major depressive disorder (MDD) is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment. MDD is also a complex and heterogeneous disorder, at etiological, phenotypical, and biological levels. The gene or series of genes, which cause MDD, have so far not been identified. However, certain genetic variations, called polymorphisms, may increase the risk of MDD in a susceptible person. In addition, environmental stress also is a common precipitating factor of MDD. Various stressful life-experiences-prenatal stress, aversive early life experiences, ongoing or recent psychosocial stress-are important en-vironmental factors contributing to the development of MDD. Nevertheless, not all persons ex-posed to these stresses become depressed. Environmental stress interacts with a person’s ge-netic makeup to influence his or her risk for developing MDD. It is the combination of genes, early life stress, and ongoing stress, which may ultimately determine an individual’s responsiveness to stress and vulnerability to MDD. Consequently, the gene and environment interactions may impact multiple neurobiological systems implicated in MDD. The gene-environment interaction in the pa-thophysiology of MDD leads to advances in personalized medicine by means of genotyping for inter-individual variability in drug action and metabolism. Such concept may explain why some subjects become depressed while others remain unaffected.

참고문헌 (72)

  1. Kessler RC, "The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)", JAMA, 289, pp.3095~3105 (2003)
  2. Association AP, "Diagnostic and Statistical Manual of Mental Disorders" (2000), American Psychiatric Association
  3. Frank E, "Natural history and preventative treatment of recurrent mood disorders", Annu Rev Med, 50, pp.453~468 (1999)
  4. Aina Y, "Understanding comorbidity with depression and anxiety disorders", J Am Osteopath Assoc, 106, pp.S9~S14 (2006)
  5. Robinson MJ, "Depression and pain", Front Biosci, 14, pp.5031~5051 (2009)
  6. Charney DS, "Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention", Sci STKE, 2004, pp.re5~ (2004)
  7. Wurtman RJ, "Genes, stress, and depression", Metabolism, 54, pp.16~19 (2005)
  8. Caspi A, "Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene", Science, 301, pp.386~389 (2003)
  9. Schildkraut JJ, "The catecholamine hypothesis of affective disorders: a review of supporting evidence", Am J Psychiatry, 122, pp.509~522 (1965)
  10. Rosenthal NE, "Monoamine metabolites in cerebrospinal fluid of depressive subgroups", Psychiatry Res, 2, pp.113~119 (1980)
  11. Heninger GR, "Noradrenergic and serotonergic receptor system function in panic disorder and depression", Acta Psychiatr Scand Suppl, 341, pp.138~150 (1988)
  12. Ruhe HG, "Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies", Mol Psychiatry, 12, pp.331~359 (2007)
  13. Jans LA, "Serotonergic vulnerability and depression: assumptions, experimental evidence and implications", Mol Psychiatry, 12, pp.522~543 (2007)
  14. Lesch KP, "Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region", Science, 274, pp.1527~1531 (1996)
  15. Munafo MR, "Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis", Biol Psychiatry, 63, pp.852~857 (2008)
  16. Neumeister A, "Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression", Arch Gen Psychiatry, 59, pp.613~620 (2002)
  17. Kendler KS, "The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication", Arch Gen Psychiatry, 62, pp.529~535 (2005)
  18. Zalsman G, "Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression", Am J Psychiatry, 163, pp.1588~1593 (2006)
  19. Cervilla JA, "The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-Gene cohort", Mol Psychiatry, 12, pp.748~755 (2007)
  20. Kilpatrick DG, "The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults", Am J Psychiatry, 164, pp.1693~1699 (2007)
  21. Lemonde S, "Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide", J Neurosci, 23, pp.8788~8799 (2003)
  22. Zill P, "SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression", Mol Psychiatry, 9, pp.1030~1036 (2004)
  23. Schmidt HD, "The role of neurotrophic factors in adult hip-pocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior", Behav Pharmacol, 18, pp.391~418 (2007)
  24. Martinowich K, "Interaction between BDNF and serotonin: role in mood disorders", Neuropsychopharmacology, 33, pp.73~83 (2008)
  25. Bath KG, "Variant BDNF (Val66Met) impact on brain structure and function", Cogn Affect Behav Neurosci, 6, pp.79~85 (2006)
  26. Duman RS, "A neurotrophic model for stress-related mood disorders", Biol Psychiatry, 59, pp.1116~1127 (2006)
  27. Martinowich K, "New insights into BDNF function in depression and anxiety", Nat Neurosci, 10, pp.1089~1093 (2007)
  28. Pezawas L, "The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology", J Neurosci, 24, pp.10099~10102 (2004)
  29. Kim JM, "Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders", Biol Psychiatry, 62, pp.423~428 (2007)
  30. Nestler EJ, "The mesolimbic dopamine reward circuit in depression", Biol Psychiatry, 59, pp.1151~1159 (2006)
  31. Elovainio M, "Genetic variants in the DRD2 gene moderate the relationship between stressful life events and depressive symptoms in adults: cardiovascular risk in young Finns study", Psychosom Med, 69, pp.391~395 (2007)
  32. Heim C, "The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies", Biol Psychiatry, 49, pp.1023~1039 (2001)
  33. Ezquiaga E, "Psychosocial factors and episode number in depression", J Affect Disord, 12, pp.135~138 (1987)
  34. Huizink AC, "Prenatal stress and risk for psychopathology: specific effects or induction of general susceptibility?", Psychol Bull, 130, pp.115~142 (2004)
  35. Kofman O, "The role of prenatal stress in the etiology of developmental behavioural disorders", Neurosci Biobehav Rev, 26, pp.457~470 (2002)
  36. Maccari S, "Prenatal stress and long-term consequences: implications of glucocorticoid hormones", Neurosci Biobehav Rev, 27, pp.119~127 (2003)
  37. Vanbesien-Mailliot CC, "Prenatal stress has pro-inflammatory consequences on the immune system in adult rats", Psychoneuroendocrinology, 32, pp.114~124 (2007)
  38. Heim C, "The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders", Biol Psychiatry, 46, pp.1509~1522 (1999)
  39. Kaufman J, "Effects of early adverse experiences on brain structure and function: clinical implications", Biol Psychiatry, 48, pp.778~790 (2000)
  40. Gunnar MR, "Social regulation of the cortisol levels in early human development", Psychoneuroendocrinology, 27, pp.199~220 (2002)
  41. Mirescu C, "Early life experience alters response of adult neurogenesis to stress", Nat Neurosci, 7, pp.841~846 (2004)
  42. Gillespie NA, "The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression", Psychol Med, 35, pp.101~111 (2005)
  43. Surtees PG, "Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder", Biol Psychiatry, 59, pp.224~229 (2006)
  44. Neumeister A, "Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls", Arch Gen Psychiatry, 63, pp.978~986 (2006)
  45. Bradley RG, "Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene", Arch Gen Psychiatry, 65, pp.190~200 (2008)
  46. Kaufman J, "Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children", Biol Psychiatry, 59, pp.673~680 (2006)
  47. Wichers M, "The BDNF Val(66)Met x 5-HTTLPR x child adversity interaction and depressive symptoms: an attempt at replication", Am J Med Genet B Neuropsychiatr Genet, 147B, pp.120~123 (2008)
  48. Aguilera M, "Early adversity and 5-HTT", BDNF genes: new evidence of geneenvironment interactions on depressive symptoms in a general population, 2009, pp.39, 1425~1432
  49. Cicchetti D, "Interactions of child maltreatment and serotonin transporter and monoamine oxidase A polymorphisms: depressive symptomatology among adolescents from low socioeconomic status backgrounds", Dev Psychopathol, 19, pp.1161~1180 (2007)
  50. Sheline YI, "3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity", Biol Psychiatry, 48, pp.791~800 (2000)
  51. Jankord R, "Limbic regulation of hypothalamo-pituitaryadrenocortical function during acute and chronic stress", Ann N Y Acad Sci, 1148, pp.64~73 (2008)
  52. Koenigs M, "The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex", Behav Brain Res, 201, pp.239~243 (2009)
  53. Leppanen JM, "Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings", Curr Opin Psychiatry, 19, pp.34~39 (2006)
  54. Nestler EJ, "Neurobiology of depression", Neuron, 34, pp.13~25 (2002)
  55. Wise RA, "Brain reward circuitry: insights from unsensed incentives", Neuron, 36, pp.229~240 (2002)
  56. Pariante CM, "The HPA axis in major depression: classical theories and new developments", Trends Neurosci, 31, pp.464~468 (2008)
  57. Lanni C, "Depression and antidepressants: molecular and cellular aspects", Cell Mol Life Sci, 66, pp.2985~3008 (2009)
  58. Thase ME, "The clinical, psychosocial, and pharmacoeconomic ramifications of remission", Am J Manag Care, 7, pp.S377~S385 (2001)
  59. Duman RS, "Synaptic plasticity and mood disorders", Mol Psychiatry, 7(Suppl 1), pp.S29~S34 (2002)
  60. Sheline YI, "Neuroimaging studies of mood disorder effects on the brain", Biol Psychiatry, 54, pp.338~352 (2003)
  61. Merens W, "Residual cognitive impairments in remitted depressed patients", Depress Anxiety, 25, pp.E27~E36 (2008)
  62. Segal ZV, "Cognitive reactivity to sad mood provocation and the prediction of depressive relapse", Arch Gen Psychiatry, 63, pp.749~755 (2006)
  63. Binneman B, "A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression", Am J Psychiatry, 165, pp.617~620 (2008)
  64. aan het Rot M, "Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression", Biol Psychiatry, 67, pp.139~145 (2010)
  65. Perlis RH, "When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study", Neuropsychopharmacology, 34, pp.2227~2236 (2009)
  66. Brown C, "Clinical presentations of major depression by African Americans and whites in primary medical care practice", J Affect Disord, 41, pp.181~191 (1996)
  67. Page AC, "Outcomes for depressed and anxious inpatients discharged before or after group cognitive behavior therapy: a naturalistic comparison", J Nerv Ment Dis, 191, pp.653~659 (2003)
  68. Conca A, "Transcranial magnetic stimulation: a novel antidepressive strategy?", Neuropsychobiology, 34, pp.204~207 (1996)
  69. Kuhn J, "Deep brain stimulation as a new therapeutic approach in therapy-resistant mental disorders: ethical aspects of investigational treatment", Eur Arch Psychiatry Clin Neurosci, 259(Suppl 2), pp.S135~S141 (2009)
  70. George MS, "Vagus nerve stimulation. A potential therapy for resistant depression?", Psychiatr Clin North Am, 23, pp.757~783 (2000)
  71. Crowley K, "A critical examination of bifrontal electroconvulsive therapy: clinical efficacy, cognitive side effects, and directions for future research", J ECT, 24, pp.268~271 (2008)
  72. Castren E, "Is mood chemistry?", Nat Rev Neurosci, 6, pp.241~246 (2005)

이 간행물의 다른 논문 (17건)

영조는 치매였나?김기웅pp. 532-532정신건강의학과로의 개명이 우리에게 주는 것?안동현pp. 533-537한국형 범불안장애 약물치료 알고리듬 2009 ( I ) : 초기 치료 전략이상혁, 서호석, 이준엽, 유범희, 김민숙, 김찬형, 양종철pp. 546-552한국형 범불안장애 약물치료 알고리듬 2009 ( II ) : 약물치료 알고리듬 및 장기 약물치료 전략김민숙, 서호석, 이상혁, 양종철, 김찬형, 유범희, 이준엽pp. 553-563한국형 범불안장애 약물치료 알고리듬 2009 (III) : 공존질환의 치료이상혁, 유범희, 김찬형, 양종철, 이준엽, 서호석, 김민숙pp. 564-569
원문 보기